Retatrutide, by Soma Pharmaceuticals , represents a exciting development in weight control . This dual-action compound combines GLP-1 receptor agonist activity with another receptor activation , indicating remarkable efficacy in clinical data for metabolic reduction . Experts believe this treatment could offer a different option for patients facing